| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Full Paper |
1 Oxford Project to Investigate Memory and Ageing, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, 2 Magnetic Resonance Unit, MRC Clinical Sciences Centre, Hammersmith Hospital, London and 3 Department of Statistics, University of Oxford, Oxford, UK
A surrogate marker is needed for Alzheimer's disease (AD) both to aid diagnosis and to assess interventions. Despite widespread use, brain imaging markers have largely been confounded by overlap with "normal" ageing. 39 elderly subjects completed up to four serial volumetric brain MRI scans with intervals from 2.5 months to 7 months. By National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria, five subjects had probable AD, two possible AD and 32 were negative for AD, although this group included memory-impaired subjects. Total brain and ventricular volumes were measured for each scan, and rates of change for each interval calculated. The rate of change in ventricle-to-brain ratio was 15.6% per year (standard deviation (SD) 2.8%) for probable AD compared with 4.3% per year (SD 1.1%) for negative AD (p<0.001). There was no significant difference between these groups' mean ventricle-to-brain ratios measured at a single time point (p=0.25). Rates of change in brain or ventricular volume over time also differed between the two groups (p<0.001). Power calculations reveal that to detect a 20% reduction in the excess rate of atrophy of a probable AD cohort in just 6 months, with 90% power, 135 subjects would be required in each arm of a randomized placebo controlled trial. For a 30% reduction in the excess rate of atrophy, 61 subjects would be required. Rate of change analysis makes serial brain MRI a valuable surrogate marker for Alzheimer's disease. Since only 6 months or less is required between scans, this procedure has both clinical relevance and potential for monitoring interventions.
This article has been cited by other articles:
 |
|
 |
|
  A. Vogiatzoglou, H. Refsum, C. Johnston, S. M. Smith, K. M. Bradley, C. de Jager, M. M. Budge, and A. D. Smith Vitamin B12 status and rate of brain volume loss in community-dwelling elderly Neurology, September 9, 2008; 71(11): 826 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Nestor, R. Rupsingh, M. Borrie, M. Smith, V. Accomazzi, J. L. Wells, J. Fogarty, R. Bartha, and the Alzheimer's Disease Neuroimaging Initiative Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database Brain, September 1, 2008; 131(9): 2443 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Sluimer, W. M. van der Flier, G. B. Karas, N. C. Fox, P. Scheltens, F. Barkhof, and H. Vrenken Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients Radiology, August 1, 2008; 248(2): 590 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H Rosenberg Rethinking brain food Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1259 - 1260. [Full Text] [PDF]
|
|
|
|
 |
|
 E.K. Herrmann, K. Hahn, C. Kratzer, I. von Seggern, C. Zimmer, and E. Schielke Status Epilepticus as a Risk Factor for Postencephalitic Parenchyma Loss Evaluated by Ventricle Brain Ratio Measurement on MR Imaging AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1245 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schott, S. L. Price, C. Frost, J. L. Whitwell, M. N. Rossor, and N. C. Fox Measuring atrophy in Alzheimer disease: A serial MRI study over 6 and 12 months Neurology, July 12, 2005; 65(1): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |
